BioTech startup Synthace gets £7.3m Series A

Sep 20, 2017 · uktech.news

BioTech firm Synthace has raised £7.3m in Series A funding from investors including White Cloud Capital, Amadeus Capital Partners and Eleven Two Capital.

Existing shareholders Sofinnova Partners, SOSV and Bioeconony Capital also participated.

The company, which has created proprietary language and software platform Antha specifically for biologists, says it will use the cash to gain further traction and expand in the market.

Antha, the company says, is designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment.

Synthace CEO Tim Fell said: "Our need to heal, feed, fuel and manufacture for a growing population can be met by unlocking the near infinite power of biology but only by bringing software abstraction and more automation to biological R&D and manufacturing, and by enabling biologists to build atop their collective work. That is what the Antha platform does, and why we are so passionate about realizing its potential."

Read Complete Article

RT @sfagency: Do not miss this #talk on #teams with legend @alisoncoward from @bracketagency - you'll be sorry if you do 🤓 via @techdotlon…

1 million EU citizens live in London. Government must ensure any new registration system is quick & simple, with th… https://t.co/ok0WU8bSwC

RT @catalyst_au: On Saturday we completed our 12th international mission, this one to London for @LDNTechWeek with 16 participants from acr…

Linux and open-source jobs are in more demand than ever https://t.co/kq38XL4MBI

ACMA unveils NBN consumer standards https://t.co/lvw5GG88x6 by @thelaughingsub